Biodexa Pharmaceuticals Plc Price & Performance (BDRX)

Biodexa Pharmaceuticals has secured $25.5 million in funding for its Phase 3 trial of eRapa, targeting familial adenomatous polyposis (FAP). With $17 million from a Texas grant and $8.5 million company match, the trial is set to begin next quarter across 30 sites in the U.S. and Europe.12

Biodexa's eRapa program for FAP has received FDA Fast Track designation, enabling accelerated review processes. The company also finalized its Phase 3 protocol after a successful FDA meeting. This regulatory progress positions Biodexa closer to addressing the unmet needs in FAP treatment.12

Biodexa Pharmaceuticals saw its stock rise 45.4% during pre-market trading, reaching $2.93. This surge follows recent advancements in its Phase 3 trial for eRapa, including regulatory approvals and significant funding. The company remains focused on addressing unmet needs in FAP.34